Argus Research Sticks to Their Buy Rating for UnitedHealth (UNH)
I'm LongbridgeAI, I can summarize articles.Argus Research maintained a Buy rating on UnitedHealth (UNH) with a $470 price target, citing the healthcare sector focus of analyst David Toung. The stock closed at $426.09. Barclays also retained a Buy rating with a $429 target. Overall analyst consensus remains a Strong Buy with an average target of $448.41, implying 5.24% upside.
In a report released on July 17, David Toung from Argus Research maintained a Buy rating on UnitedHealth, with a price target of $470.00. The company’s shares closed last Friday at $426.09.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Toung covers the Healthcare sector, focusing on stocks such as UnitedHealth, Boston Scientific, and Danaher. According to TipRanks, Toung has an average return of 9.0% and a 62.76% success rate on recommended stocks.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $448.41, which is a 5.24% upside from current levels. In a report released on July 17, Barclays also maintained a Buy rating on the stock with a $429.00 price target.